NO20012017L - Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose - Google Patents
Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenoseInfo
- Publication number
- NO20012017L NO20012017L NO20012017A NO20012017A NO20012017L NO 20012017 L NO20012017 L NO 20012017L NO 20012017 A NO20012017 A NO 20012017A NO 20012017 A NO20012017 A NO 20012017A NO 20012017 L NO20012017 L NO 20012017L
- Authority
- NO
- Norway
- Prior art keywords
- vegf
- gene
- protein
- prevent restenosis
- growth factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10558798P | 1998-10-26 | 1998-10-26 | |
PCT/US1999/024054 WO2000024412A2 (en) | 1998-10-26 | 1999-10-26 | Use of vegf-c or vegf-d gene or protein to prevent restenosis |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20012017D0 NO20012017D0 (no) | 2001-04-24 |
NO20012017L true NO20012017L (no) | 2001-06-26 |
Family
ID=22306672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20012017A NO20012017L (no) | 1998-10-26 | 2001-04-24 | Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1126870B1 (zh) |
JP (2) | JP4769929B2 (zh) |
CN (1) | CN1338943A (zh) |
AT (1) | ATE275417T1 (zh) |
AU (1) | AU768330B2 (zh) |
CA (1) | CA2340593C (zh) |
DE (1) | DE69920031T2 (zh) |
ES (1) | ES2229788T3 (zh) |
NO (1) | NO20012017L (zh) |
NZ (1) | NZ510121A (zh) |
PT (1) | PT1126870E (zh) |
WO (1) | WO2000024412A2 (zh) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6818220B1 (en) | 1994-11-14 | 2004-11-16 | Licentia Ltd. | Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof |
US6361946B1 (en) | 1997-02-05 | 2002-03-26 | Licentia Ltd | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
JP4981229B2 (ja) | 2000-02-25 | 2012-07-18 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ハイブリッド血管内皮成長因子DNAsおよびタンパク質に関与する物質および方法 |
AU2001268149B2 (en) * | 2000-06-01 | 2005-08-18 | University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
TWI257307B (en) | 2000-07-12 | 2006-07-01 | Orthologic Corp | Pharmaceutical composition for cardiac tissue repair |
CN1211126C (zh) | 2000-08-04 | 2005-07-20 | 人体基因组科学有限公司 | 血管内皮生长因子2 |
DK2314293T3 (en) * | 2001-01-16 | 2017-04-18 | Vascular Therapies Llc | IMPLANTABLE DEVICE CONTAINING RESORBABLE MATERIAL MATERIAL AND RAPAMYCINE FOR PREVENTION OR TREATMENT OF VASCULOPROLIFERATIVE DISEASES |
EP2228389B1 (en) | 2001-04-13 | 2015-07-08 | Human Genome Sciences, Inc. | Antibodies against vascular endothelial growth factor 2 |
FI20010898A0 (fi) * | 2001-04-30 | 2001-04-30 | Ylae Herttuala Seppo | Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi |
GB0120690D0 (en) | 2001-08-24 | 2001-10-17 | Novartis Ag | Organic compounds |
JP2006503605A (ja) * | 2002-04-30 | 2006-02-02 | フイット バイオテク オーワイジェイ ピーエルシー | 医療装置 |
PL195457B1 (pl) * | 2002-08-05 | 2007-09-28 | Zaklady Farm Polpharma Sa | Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie |
WO2005039556A1 (ja) * | 2003-10-29 | 2005-05-06 | Institute Of Medicinal Molecular Design. Inc. | 血行再建術後の再狭窄又は再閉塞の治療及び/又は予防のための医薬 |
EP1726318A1 (en) * | 2004-03-18 | 2006-11-29 | Kensuke Egashira | Medicine/gene leaching type stent |
ES2363758T3 (es) | 2005-08-15 | 2011-08-16 | Vegenics Pty Ltd | Vegf y pdgf modificados con propiedades angiogénicas mejoradas. |
CN101563102B (zh) | 2006-09-22 | 2014-12-17 | 德克萨斯***大学董事会 | 治疗内皮功能障碍的方法 |
EP2244740A1 (en) | 2008-02-19 | 2010-11-03 | Celladon Corporation | Compositions for enhanced uptake of viral vectors in the myocardium |
CN101361988B (zh) * | 2008-09-12 | 2011-12-21 | 西南交通大学 | 一种具有生物相容性的血管支架或心脏瓣膜表面涂层的制备方法 |
WO2012088563A1 (en) * | 2010-11-24 | 2012-07-05 | Vegenics Pty Limited | Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof |
CN108640994A (zh) * | 2018-06-28 | 2018-10-12 | 浙江众意生物科技有限公司 | 一种vegf-c单克隆抗体及试剂盒 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998033917A1 (en) * | 1994-11-14 | 1998-08-06 | The Ludwig Institute For Cancer Research | Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
US5830879A (en) * | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
DK0956339T3 (da) * | 1996-08-23 | 2006-01-30 | Licentia Oy | Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D) |
US6013780A (en) * | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
JP2001524828A (ja) * | 1997-04-25 | 2001-12-04 | コラテラル・セラピューティクス | 切断型vegf関連蛋白質 |
-
1999
- 1999-10-26 CN CN99812544A patent/CN1338943A/zh active Pending
- 1999-10-26 WO PCT/US1999/024054 patent/WO2000024412A2/en active IP Right Grant
- 1999-10-26 PT PT99956559T patent/PT1126870E/pt unknown
- 1999-10-26 JP JP2000578021A patent/JP4769929B2/ja not_active Expired - Fee Related
- 1999-10-26 NZ NZ510121A patent/NZ510121A/xx unknown
- 1999-10-26 DE DE69920031T patent/DE69920031T2/de not_active Expired - Lifetime
- 1999-10-26 AT AT99956559T patent/ATE275417T1/de not_active IP Right Cessation
- 1999-10-26 AU AU13147/00A patent/AU768330B2/en not_active Ceased
- 1999-10-26 CA CA2340593A patent/CA2340593C/en not_active Expired - Fee Related
- 1999-10-26 ES ES99956559T patent/ES2229788T3/es not_active Expired - Lifetime
- 1999-10-26 EP EP99956559A patent/EP1126870B1/en not_active Expired - Lifetime
-
2001
- 2001-04-24 NO NO20012017A patent/NO20012017L/no unknown
-
2011
- 2011-01-27 JP JP2011015549A patent/JP5231587B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
PT1126870E (pt) | 2005-01-31 |
DE69920031D1 (de) | 2004-10-14 |
JP2011173874A (ja) | 2011-09-08 |
JP2002528420A (ja) | 2002-09-03 |
WO2000024412A2 (en) | 2000-05-04 |
ATE275417T1 (de) | 2004-09-15 |
NO20012017D0 (no) | 2001-04-24 |
WO2000024412A3 (en) | 2000-08-03 |
CA2340593A1 (en) | 2000-05-04 |
AU1314700A (en) | 2000-05-15 |
AU768330B2 (en) | 2003-12-11 |
NZ510121A (en) | 2003-02-28 |
EP1126870B1 (en) | 2004-09-08 |
JP5231587B2 (ja) | 2013-07-10 |
CN1338943A (zh) | 2002-03-06 |
EP1126870A2 (en) | 2001-08-29 |
JP4769929B2 (ja) | 2011-09-07 |
CA2340593C (en) | 2012-05-08 |
DE69920031T2 (de) | 2005-09-22 |
ES2229788T3 (es) | 2005-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20012017D0 (no) | Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose | |
Opperman et al. | TGF‐β1, TGF‐β2, and TGF‐β3 exhibit distinct patterns of expression during cranial suture formation and obliteration in vivo and in vitro | |
Hultgårdh-Nilsson et al. | Expression of phenotype-and proliferation-related genes in rat aortic smooth muscle cells in primary culture | |
ATE163046T1 (de) | Genetische veränderung von endothelzellen | |
Kallassy et al. | Patched (ptch)-associated preferential expression of smoothened (smoh) in human basal cell carcinoma of the skin | |
ATE269402T1 (de) | Ikk-beta proteine, nukleinsäuren und verfahren | |
TR199902818T2 (xx) | Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler. | |
DK0814827T3 (da) | Karendotel-vækstfaktor-B | |
BRPI9809387B8 (pt) | anticorpo humanizado anti-fator de crescimento endotelial vascular humano e composição que o compreende | |
EP0974359A3 (en) | FSH and FSH variant formulations, products and methods | |
SE8902532L (sv) | Bestaemning av plasmaproteiner | |
NO881670L (no) | Diagnostisk proeve paa inhibitor for plasminogenaktivatorerav vev- og urokinasetype, samt gen som koder for inhibitoren. | |
AU8267698A (en) | Method for coating stents with dna and expression of recombinant genes from dna coated stent in vivo | |
WO1999045098A3 (en) | Delivery or proteins into eukaryotic cells with recombinant yersinia | |
DK1025237T3 (da) | Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder | |
ATE294236T1 (de) | Promotor der tie rezeptor protein kinase | |
WO2003039491A3 (en) | Novel isoforms of vascular endothelial cell growth inhibitor | |
ATE203766T1 (de) | Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose | |
DE69534633D1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
NO20006026L (no) | Fremgangsmåter og blandinger for modulering av angiogenese ved bruk av tyrosin kinase SRC | |
DE60035426D1 (de) | Genomisches peroxidasegen von ipomea batatas und dessen promotor | |
DK1095032T3 (da) | Hidtil ukendte fluorescerende CYP2D-assayreagenser | |
DE60017924D1 (de) | Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose | |
DE59712847D1 (de) | Monoklonaler Antikörper gegen MxA und MxB | |
BG105682A (en) | Bone stimulating factor |